Wei Fu

Wei Fu has worked in the biotechnology industry since 2009. Wei began their career at West Virginia University as an Associate Research Scientist, where they developed stable cell lines, elucidated the role of FAK in cancer cell motility and metastasis, and optimized a lenti-viral vector. In 2011, they joined OriGene Technologies, Inc. as a Research Scientist and Project Manager & Group Leader, where they were responsible for leading immunology R/D group on antibody products development and management, and generating and developing all the antibody conjugation SOP for multiple applications. In 2017, they joined BioCheck, Inc. as a Scientist and Project Manager. Most recently, they have been the Vice President of Antibody Development at OriGene Technologies since 2018.

Wei Fu obtained a Doctor of Medicine (MD) from China Medical University in the field of Clinical Medicine. Wei also holds a Master's degree from China Medical University in Cell Physiology.